Click text to download the following document: Biomarkers Consortium Project Use of Targeted Multiplex Proteomic Strategies to Identify Plasma-Based Biomarkers in Alzheimers Disease The data described within this document represents the work of the Biomarkers Consortium Project Use of Targeted Multiplex Proteomic Strategies to Identify Plasma-Based Biomarkers in Alzheimers Disease. This project was submitted to […]
Continue reading...Monday, October 4, 2010
Comments Off on New Warnings from PET Core
All site 128 PIB scans have been re-reconstructed over the past several months. The new reconstruction code has a new scatter correction algorithm implemented, resulting in from some less to much less scatter being subtracted, particularly in the lower slices, e.g. those that include the normalizing region, cerebellar gray matter. There are 47 reworked PiB? […]
Continue reading...Thursday, August 12, 2010
Comments Off on New York Times Article highlights ADNI
Sharing of Data Leads to Progress on Alzheimers By GINA KOLATA “In 2003, a group of scientists and executives from the National Institutes of Health, the Food and Drug Administration, the drug and medical-imaging industries, universities and nonprofit groups joined in a project that experts say had no precedent: a collaborative effort to find the […]
Continue reading...Friday, May 21, 2010
Comments Off on ADNI: progress report and future plans.
The Alzheimers Disease Neuroimaging Initiative (ADNI) beginning in October 2004, is a 6-year research project that studies changes of cognition, function, brain structure and function, and biomarkers in elderly controls, subjects with mild cognitive impairment, and subjects with Alzheimers disease (AD). A major goal is to determine and validate MRI, PET images, and cerebrospinal fluid […]
Continue reading...Friday, May 21, 2010
Comments Off on Update on the Biomarker Core of ADNI subjects
Here, we review progress by the Penn Biomarker Core in the Alzheimers Disease Neuroimaging Initiative (ADNI) toward developing a pathological cerebrospinal fluid (CSF) and plasma biomarker signature for mild Alzheimers disease (AD) as well as a biomarker profile that predicts conversion of mild cognitive impairment (MCI) and/or normal control subjects to AD. Authors: Trojanowski JQ, […]
Continue reading...Friday, May 21, 2010
Comments Off on Clinical Core of ADNI: progress and plans
The Clinical Core of the Alzheimers Disease Neuroimaging Initiative (ADNI) has provided clinical, operational, and data management support to ADNI since its inception. This article reviews the activities and accomplishments of the core in support of ADNI aims. Authors: Aisen PS, Petersen RC, Donohue MC, Gamst A, Raman R, Thomas RG, Walter S, Trojanowski JQ, […]
Continue reading...Thursday, May 20, 2010
Comments Off on ADNI biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans.
Abstract: The role of the Alzheimers Disease Neuroimaging Initiative Genetics Core is to facilitate the investigation of genetic influences on disease onset and trajectory as reflected in structural, functional, and molecular imaging changes; fluid biomarkers; and cognitive status. Major goals include (1) blood sample processing, genotyping, and dissemination, (2) genome-wide association studies (GWAS) of longitudinal phenotypic […]
Continue reading...Monday, May 10, 2010
Comments Off on Update on the magnetic resonance imaging core of ADNI
Functions of the Alzheimers Disease Neuroimaging Initiative (ADNI) magnetic resonance imaging (MRI) core fall into three categories: (1) those of the central MRI core laboratory at Mayo Clinic, Rochester, Minnesota, needed to generate high quality MRI data in all subjects at each time point; (2) those of the funded ADNI MRI core imaging analysis groups […]
Continue reading...Monday, March 8, 2010
Comments Off on Updated Recall Speadsheet for MR Images Now Available to Researchers
The MRI Core has consolidated their image recalls into one Excel spreadsheet to allow researchers to quickly identify, modify or discard images from their study that are no longer appropriate.
Continue reading...Wednesday, May 27, 2009
Comments Off on Summary of dates of CSF Biomarker Analysis
Below is a brief summary of dates of CSF biomarker analyses run as batches of samples using the Luminex xMAP platform and Innogenetics INNO-BIA AlzBio3? immunoassay reagents. Normalization of CSF biomarker data between results of 2007 and 2008 have been obtained using a statistical approach, resulting in a procedure to maintain lot-to-lot consistency within clinical […]
Continue reading...
If you are 55 to 90 years of age you may be able to participate. Participation is free and no medication is involved.
Join
Thursday, November 18, 2010
Comments Off on New set of proteomics data will be available Friday November 19th, 2010